1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Genesystem Co., Ltd.

Genesystem Co., Ltd.

KKRX:363250
3,985.00
KRW
-65.00
(-1.60%)
-1,770.95EPS
26.08BMarket Cap
Genesystem Co., Ltd.
KRX:363250
(Korea Stock Exchange)

Recent

price

3,985.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
KRW
513.37
3,505.24
2,117.04
529.11
129.08
176.38
55.95
140.59
Revenue per Share
-1,828
-588
568
-1,303
-1,139
-1,302
-1,754
-1,431.19
Basic EPS, GAAP
-1,081.51
-551.38
29.98
-976.53
-1,184.31
-1,124.21
-1,058.93
-1,241.42
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1,875.75
1,819.6
6,408.5
5,066.46
3,930.8
2,829.85
1,151.31
1,559.54
Book Value per Share
-1,927.94
1,772.7
6,308.42
4,967.73
2,842.23
1,820.22
1,057.79
1,519.76
Tangible Book Value per Share
2
4
6
7
7
7
7
7
Basic Weighted Avg Shares
1,135
13,258
13,237
3,653
897
1,208
381
1,010
Sales/Revenue/Turnover
-219.78
25.46
17.12
-180.8
-1,057.1
-837.45
-2,540.06
-777.3
Operating Margin (%)
136
250
308
386
545
1,242
1,018
568
Depreciation Expense
-4,041
-2,224
3,551
-8,996
-7,915
-8,915
-11,955
-10,282
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-356.08
-16.77
26.83
-246.26
-882.41
-738.17
-3,134.97
-1,017.98
Profit Margin (%)
-9,454
8,742
38,870
28,496
18,608
7,444
209
5,834
Working Capital
38
3,012
3,119
3,087
3,107
2,269
2,129
1,976
LT Debt
-12,696
12,316
44,085
35,110
30,684
21,881
7,747
11,651
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
12.59
-22.72
-25.3
-38.16
-88.15
-75.66
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,916
1,884
1,911
LT Borrowings
1,944
1,944
1,875
LT Finance Leases
185
151
101
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
8
8
Market Capitalization
27,964
51,179
26,082

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,747
6,242
8,084
Cash, Cash Equivalents & STI
1,874
5,107
4,820
Accounts Receivable, Net
7
52
626
Inventories
649
679
833
Total Current Liabilities
2,538
2,380
2,250
Payables & Accruals
- -
- -
- -
ST Debt
1,916
1,884
1,911
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
26.34%
-64.59%
Free Cash Flow
- -
-759.22%
-6.24%
Net Income, GAAP
- -
-115.65%
34.1%
Sales/Revenue/Turnover
- -
-36.36%
-68.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
135
147
803
123
1,208
2025
63
69
90
158
381
2026
329
432
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-311
-290
-253
-427.6
-1,302
2025
-262
-326
-298.4
-868.55
-1,754
2026
-221.86
-98
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
Medtronic plc. (NYSE:MDT)
Business
Genesystem Co., Ltd. is a South Korea-based in vitro molecular diagnostics company primarily engaged in the development, manufacture, and commercialization of rapid point-of-care testing (POCT) real-time polymerase chain reaction (PCR) platforms, microfluidic biochips, and diagnostic reagent kits. Founded in 2010 and headquartered in Daejeon, South Korea, the company serves clinical healthcare providers, veterinary clinics, research laboratories, and food safety institutions across domestic and international markets, including Asia-Pacific, Europe, the Middle East, and the Americas. Genesystem operates through integrated diagnostic product lines and services, which include: point-of-care molecular diagnostic instruments under the GENECHECKER brand, featuring the UF-100, UF-150, and UF-300 series ultra-fast real-time quantitative PCR analyzers; proprietary microfluidic lab-on-a-chip consumables, such as Rapi-Disk biochips, SMART CHEK microfluidic reaction plates, and specialized optical assay cartridges; human clinical diagnostic assay kits under the SMARTCHEK brand, spanning multiplex respiratory infection panels (including COVID-19, influenza A/B, and respiratory syncytial virus), tuberculosis, human papillomavirus (HPV), sexually transmitted infections, and vector-borne tropical diseases; companion animal and veterinary diagnostic kits designed for rapid on-site detection of canine and feline respiratory and enteric pathogens; food safety testing kits targeting common foodborne bacterial pathogens; and original equipment manufacturing (OEM) and custom assay development services for diagnostic biochip systems. In recent strategic and operational developments, Genesystem has expanded its international commercialization network by securing strategic distribution agreements in Southeast Asian and Middle Eastern markets, broadened its veterinary diagnostics business through partnerships with animal healthcare networks, introduced next-generation multi-channel real-time PCR diagnostic systems and expanded multiplex infectious disease test menus, and scaled automated cleanroom manufacturing facilities to increase commercial biochip production capacity.